MedTrace Logo

Phase I/Ib Clinical Trial of ABTL0812 in Advanced Cancer Patients

NCT02201823 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2015-07-02

No results posted yet for this study

Summary

Ability Pharmaceuticals promotes a clinical trial to determine the adequate dose of a new drug, ABTL0812, that will be administered orally daily to patients with advanced solid tumors.

Conditions

Interventions

DRUG

ABTL0812

ABTL0812. Five cohorts and one extension phase.

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    collaborator OTHER

  • Institut Català d'Oncologia

    collaborator OTHER

  • Ability Pharmaceuticals SL

    lead INDUSTRY

Principal Investigators

  • Laura Vidal, MD, PhD · Hospital Clinic of Barcelona

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-03-31
Completion
2015-04-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02201823 on ClinicalTrials.gov